SPTX Seaport Therapeutics, Inc. Common Stock

QT55

Latest market price

19.94

-0.07-0.35%

Overview Short InterestFilings

SPTXQT55Seaport Therapeutics, Inc. Common Stock·NASDAQ

Overview Short InterestFilings

19.94-0.35%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE+0.30%$23.04 RARE+2.39%$16.69 NUVB+2.35%$4.70 TRAX+1.17%$45.58 NTLA+3.95%$12.12 ABSI+5.42%$10.21 URGN-0.50%$34.19 MAZE+1.94%$30.96

Snapshot

Index	—	P/E	—	EPS (ttm)	—	Insider Own	31.19%	Shs Outstand	53.53M	Perf Week	-3.94%

Market Cap	1.07B	Forward P/E	—	EPS next Y	-2.54	Insider Trans	0.08%	Shs Float	18.43M	Perf Month	8.63%

Enterprise Value	803.15M	PEG	—	EPS next Q	—			Short Float	20.17%	Perf Quarter	-6.63%

Income	-75.00M	P/S	—	EPS this Y	—			Short Ratio	19.64	Perf Half Y	17.71%

Sales	0.00	P/B	2.53	EPS next Y	—	ROA	-19.93%	Short Interest	3.72M	Perf YTD	-4.71%

Book/sh	7.90	P/C	3.92	EPS next 5Y	—	ROE	-57.34%	52W High	28.38 -29.74%	Perf Year	—

Cash/sh	5.10	P/FCF	—	EPS past 3/5Y	—	ROIC	-21.83%	52W Low	14.85 34.28%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	8.14% 7.33%	Perf 5Y	—

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	1.57	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	18.00	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	50.77	Recom	1.88

Dividend Gr. 3/5Y	—	Current Ratio	18.00	EPS Q/Q	72.47%	SMA20	5.85%	Beta	0.75	Target Price	38.50

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	—	SMA50	-5.05%	Rel Volume	2.42	Prev Close	20.01

Employees	58	LT Debt/Eq	0.01	Earnings	Mar 03	SMA200	-0.59%	Avg Volume	217.88K	Price	19.94

IPO Date	May 01, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	15.52% —	Net Debt/EBITDA	—	Volume	527,902	Change	-0.35%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-14-26	Initiated	Canaccord	Buy	$28
Sep-25-26	Initiated	Raymond James	Strong Buy	$46
Aug-25-26	Initiated	Jones	Buy	$32
Aug-04-26	Reiterated	HC Wainwright & Co.	Buy	$50
Jul-15-26	Initiated	H.C	Buy	$50
May-26-26	Initiated	Leerink	Outperform	$35
May-26-26	Initiated	Stifel	Buy	$30
May-26-26	Initiated	JPMorgan	Overweight	$42

Latest News· Times ET

Nov-02-26

Nov-02-2607:00AM

Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressYahoo

Oct-29-26

Oct-29-2603:27AM

Seaport Therapeutics: Borrowed Efficacy, Engineered Safety, And A Post-IPO Discountseekingalpha.com

Oct-25-26

Oct-25-2606:08PM

Is Seaport Therapeutics (SPTX) Overvalued Based On Book Value?Yahoo

Oct-14-26

Oct-14-2604:30AM

This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga

Oct-09-26

Oct-09-2602:00PM

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congressgurufocus.com

08:00AM

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congressgurufocus.com

Oct-07-26

Oct-07-2601:00PM

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep DisturbanceYahoo

07:00AM

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbancebusinesswire.com

Oct-03-26

Oct-03-2604:41AM

Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up – Should You Buy?defenseworld.net

Oct-02-26

Oct-02-2605:41AM

Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Down – What’s Next?defenseworld.net

Sep-28-26

Sep-28-2604:15AM

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57defenseworld.net

Sep-25-26

Sep-25-2604:30AM

This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga

Sep-22-26

Sep-22-2606:03AM

PureTech Health H1 Earnings Call HighlightsYahoo

Sep-14-26

Sep-14-2607:00AM

Seaport Therapeutics to Participate in September Investor Conferencesbusinesswire.com

Sep-10-26

Sep-10-2602:42AM

HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price TargetBenzinga

Company

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)		FY 2025 12/31/2025
Total Revenue		0
Cost of Goods Sold Incl. D&A		0
Gross Profit		0
Selling, General and Administrative Excl. Other		21
Research and Development		66
Other Operating Expense		0
Operating Income		-87
Interest Expense		0
Unusual Expense		—
Non-Operating Income (Expense)		13
Net Income Before Taxes		-74
Income Taxes		1
Consolidated Net Income		-75
Net Income From Continuing Operations		-75
Net Income		-75
EPS (Recurring)		-1.94
EPS (Basic, Before Extraordinaries)		-1.94
EPS (Diluted)		-1.94
EBITDA		-86
Other After Tax Adjustments		—
Stock Option Compensation Expense		—
Price To Earnings Ratio		—
Price To Sales Ratio		—
Gross Margin		—
Operating Margin		—
Net Margin		—
Shares Outstanding		39
Market Capitalization		—
Operating Lease Expense		—

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HOMBACH ROBERT J.	Director	Jun 22 '26	Buy	18.14	13,000	235,768	13,000	Jun 24

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.